EUVIMEDEUVIMED entdecken
Crossref

TCT-427 Impact of Treatment Allocation Knowledge on Symptoms: Insights From the Placebo-Controlled ORBITA-CTO Trial

Sarosh Khan, Uzma Sajjad, Samer Fawaz, Haroun Butt, Rupert Simpson, Abdalla Ibrahim, Craig Robertson, Sean King, Paul Kelly, Shah Mohdnazri, Christopher Cook, Ozan Demir und 6 weitere

JACC · 2026-11 · 88 (18) · B182

DOI: 10.1016/j.jacc.2026.09.541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC, 2026-11. Verfasst von Sarosh Khan und 17 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Khan, S., Sajjad, U., Fawaz, S., Butt, H., Simpson, R., Ibrahim, A., Robertson, C., King, S., Kelly, P., Mohdnazri, S., Cook, C., Demir, O., Spratt, J., Brilakis, E., Shun-Shin, M. J., Al-Lamee, R., Keeble, T., & Davies, J. (2026). TCT-427 Impact of Treatment Allocation Knowledge on Symptoms: Insights From the Placebo-Controlled ORBITA-CTO Trial. JACC, 88(18), B182. https://doi.org/10.1016/j.jacc.2026.09.541

Vancouver

Khan S, Sajjad U, Fawaz S, Butt H, Simpson R, Ibrahim A, et al. TCT-427 Impact of Treatment Allocation Knowledge on Symptoms: Insights From the Placebo-Controlled ORBITA-CTO Trial. JACC. 2026;88(18):B182. doi:10.1016/j.jacc.2026.09.541

BibTeX
@article{Khan2026,
  author = {Khan, Sarosh and Sajjad, Uzma and Fawaz, Samer and Butt, Haroun and Simpson, Rupert and Ibrahim, Abdalla and Robertson, Craig and King, Sean and Kelly, Paul and Mohdnazri, Shah and Cook, Christopher and Demir, Ozan and Spratt, James and Brilakis, Emmanouil and Shun-Shin, Matthew J. and Al-Lamee, Rasha and Keeble, Thomas and Davies, John},
  title = {TCT-427 Impact of Treatment Allocation Knowledge on Symptoms: Insights From the Placebo-Controlled ORBITA-CTO Trial},
  journal = {JACC},
  year = {2026},
  volume = {88},
  number = {18},
  pages = {B182},
  doi = {10.1016/j.jacc.2026.09.541}
}
Kostenlos starten →